Research programme: therapeutic antibodies - Abbott Laboratories/Adnexus Therapeutics

Drug Profile

Research programme: therapeutic antibodies - Abbott Laboratories/Adnexus Therapeutics

Latest Information Update: 22 Jan 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Adnexus Therapeutics
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 25 Oct 2007 Bristol-Myers Squibb acquires Adnexus Therapeutics
  • 23 Jun 2006 Compound Therapeutics is now called Adnexus Therapeutics Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top